Elvinix is developing a coordinated regenerative therapy designed to restore sufficient β-cell mass and protect the recovered cells from renewed loss.
Zealand Pharma translated this biology into a peptide designed to activate two complementary receptor pathways. Elvinix holds an exclusive license to the relevant patent families and an extensive package of preclinical data, providing a strong foundation for the program and complemented by Elvinix’s own combinatorial technology and intellectual property.
Building on this foundation, the program is designed to address not only the expansion of insulin-producing capacity, but also the protection required for durable endogenous glucose control.
Elvinix is advancing a proprietary, peptide-based combination therapy for people living with Stage 3 T1D. Designed for scalable pharmaceutical development, the program aims to restore and control the body’s natural insulin-producing capacity.
The therapy is intended to rebuild a therapeutically meaningful pool of β-cells and protect that restored capacity from renewed loss.
The long-term clinical goal is to reduce dependence on exogenous insulin by restoring durable endogenous glucose control.
Development timelines, study designs and partner arrangements are shared with qualified investors and potential partners under confidentiality.
Durable recovery requires enough insulin-producing β-cells, functioning well enough to control glucose, and protected from renewed metabolic damage and autoimmune attack. These are separate biological requirements for our therapy to address.
Expand β-cell mass to increase insulin-producing capacity.
Reduce autoimmune pressure and metabolic stress.
Simultaneous activation of two complementary receptor pathways is intended to preserve and expand insulin-producing capacity.
Elvinix’s approach is designed to shift the local environment away from cytotoxicity and toward regulation, while reducing metabolic stress on the restored cells.
Foundational science on β-cell regeneration and functional recovery.
See the publicationsThe program is supported by an extensive body of preclinical work associated with the licensed platform.*
The company has completed proprietary preclinical studies that extend the program into its intended therapeutic architecture.*
* Detailed data, study reports and supporting analyses are available to qualified investors and potential partners under confidentiality.